Myesthenia Gravis

Myasthenia gravis can be a debilitating neurological disorder that affects thousands worldwide. Thymectomy has historically been considered in patients refractory to medical therapy or with concurrent thymoma. While retrospective data and propensity matched trials have favored thymectomy in order to decrease disease severity and disease associated morbidity, no randomized data existed to clearly delineate the benefit of this practice. The reviewed paper by Wolfe et al . represents the first high-level randomized prospective study investigating the role of thymectomy in patients with non-thymomatous myasthenia gravis...

No abstract text is available yet for this article.

No abstract text is available yet for this article.

BACKGROUND: This is a review of a series of patients who presented with thymoma over the most recent 20-year period. Changes and trends in disease patterns were documented. METHODS: Data were collated retrospectively but all pathology slides were reviewed. Survival functions were estimated using the Kaplan-Meier method. RESULTS: Seventy-one patients had a partial or total thymectomy during this period for a thymoma. Average age was 55 years...

Mammalian ontogenesis and postnatal histogenesis involves the dynamic and appropriate interaction of two growth related phenomena: progression and regression. The thymus gland is the organ of the mammalian body that exhibits the most profound involution during normal postnatal histogenesis. Involution of the thymus can be compared to similarly regressive processes during the ontogeny of holometabolic insects, as well as to the spontaneous regression of neoplasms. It can be expected that in the future a better understanding of neoplastic regression will result from the comparison of ontogenetic processes from taxonomically far-removed regressive processes, and the evaluation of various factors that promote progression and regression...

Although most patients with thymoma present with a mediastinal mass amenable to surgical resection, some patients develop metastatic disease requiring systemic therapy. The majority of thymomas express somatostatin receptors as demonstrated by octreotide scanning, an observation which has prompted the clinical use of octreotide in patients with this disease. Many patients with thymoma exhibit autoimmune paraneoplastic syndromes, most frequently myesthenia gravis. We report here the case of a patient with metastatic thymoma who developed a profound autoimmune polymyositis and lupus-like syndrome that flared following treatment with octreotide and was associated with a clinical response to this agent...